logo/base Created with Sketch.

FibroScan®-Facilitated Treatment Options

wave

Guideline-Endorsed Treatment Options

Source: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://www.journal-of-hepatology.eu/action/showPdf?pii=S0168-8278%2824%2900329-5

FibroScan® Measures Two Important Components of Liver Health

Liver Stiffness by VCTE™ a correlate to fibrosis and CAP™ a correlate to steatosis. These measurements are important both together as well as looked at separately along the patient’s journey.

LSM by VCTE™ may be used as an aid in the assessment of liver fibrosis.

CAP™ may be used as an aid in the assessment of hepatic steatosis.

FibroScan® is indicated as a non-invasive aid for the clinical management, diagnosis, and monitoring of adult and pediatric patients with confirmed or suspected liver disease.

VCTE™ and CAP™ both play an important role in identifying/qualifying a patient for treatment.

CAP™ is particularly of benefit to show response to REZDIFFRA™ as it will indicate a reduction in CAP™ value if there is improvement from the drug.

Thanks to our revolutionary Guided VCTE™ technology, the examination is simpler and quicker.

FibroScan® – The Only Non-Invasive Point-of-Care Solution Referenced in the FDA Prescribing Information Label for Rezdiffra™

Following REZDIFFRA™ FDA approval on March 14th, FibroScan® is the only point-of-care non-invasive test referenced in REZDIFFRA FDA prescribing information label.2

The unique and patented biomarkers of FibroScan® (LSM by VCTE™ and CAP™) are the only biomarkers referenced BOTH in:

  • The baseline patient characteristics of the MAESTRO population describing the patients to be treated.3
  • The pharmacodynamics section describing the effect of REZDIFFRA™ on liver fat reduction.4

 

White paper soon available !

Revolutionizing Liver Disease Treatment: A Conversation with Dr. Naim Alkhouri about the First-ever Therapeutic for MASH

We recently sat down with Dr. Naim Alkhouri, Chief Medical Officer, Chief of Transplant Hepatology, and Director of the Fatty Liver Program at Arizona Liver Health to discuss a historic turning point in the fight against liver disease—the FDA’s approval of Rezdiffra™.

Dr. Alkhouri is believed to be the first physician to get a patient with fibrotic MASH approved for the drug in the U.S. The patient was identified using FibroScan® technology—the only non-invasive point-of-care solution referenced directly in the FDA prescribing information label. Thanks to its patented LSM by VCTE™ for liver fibrosis assessment and CAP™ for hepatic steatosis assessment, FibroScan® is FDA-approved for both diagnosis and ongoing monitoring of patients with suspected or confirmed liver disease.

To discuss what the new therapeutic option means for patients and the future of liver health, we asked Dr. Alkhouri to share his thoughts on the dawn of a new era in the fight against MASH and liver disease.

The Essential Role of FibroScan® in the “MAESTRO-NASH” Phase 3 trial

In “MAESTRO-NASH” Phase 3 trial supporting REZDIFFRA™ FDA approval, the proprietary biomarkers of FibroScan® (LSM by VCTE™ and CAP™) played a key role in both patient prescreening criteria and measurement of therapeutic response after 52 weeks of treatment.1

With FibroScan® identify & monitor patients to be treated with Rezdiffra™

Managing MASH Patients

FibroScan® Plays an Essential Role in the Diagnosis and Management of Patients with MASLD/MASH.

Podcast

Podcast (Echosens is Shaping the Future of Liver Health Campaign) with Dr. Alkhouri and Dr. Noureddin as speakers (part of Echosens is Shaping the Future of Liver Health campaign).

Podcast soon available !

Webinar

Webinar with Dr. Alkhouri & Dr. Noureddin as speakers and Victor de Ledinghen, Chief Medical Officer as a moderator focusing on new treatment available and what it means for the patients long-term.

Webinar soon available !

Interview

Interview with Naim Alkhouri, MD on HCPLive “Resmetirom Has Been a “Game Changer” in MASH Since FDA Approval”.
Dr. Alkhouri explains the unmet need in MASH leading up to resmetirom’s historic FDA approval and the impact its availability has had for both patients and clinicians.

Coverage & Authorization Overview

Our FibroScan® ecosystem is providing all required documentation for providers to smoothly submit prior authorization.

 

References
1. Harrison, S. A., Bedossa, P., Guy, C. D. et al. (2024), ‘A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis’, N Engl J Med, 390/6: 497–509
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/217785s000lbl.pdf
3. same as 2 – Table 7: Baseline Characteristics in Adults Patients with Noncirrhotic NASH with Stage 2 to Stage 3 Fibrosis in Trial 1
4. same as 2 – Section 2.2 Pharmacodynamics
5. K223902.pdf (fda.gov)